Earnings Impact: Recent discussions on X about Bio-Techne Corporation (TECH) have centered on its latest quarterly earnings report, which showed mixed results. Some users expressed optimism about the company's revenue growth in specific biotech segments. However, concerns linger over margin pressures amid rising costs.
Sector Trends: Broader conversations on X tie TECH to overall biotech sector performance, with some noting the stock's resilience despite market volatility. A few posts highlighted potential tailwinds from innovation in diagnostics and therapeutics. The tone reflects cautious hope for long-term growth.
Note: This discussion summary was generated from an AI condensation of post data.
Bio-Techne Corporation Insider Trading Activity
Bio-Techne Corporation insiders have traded $TECH stock on the open market 3 times in the past 6 months. Of those trades, 0 have been purchases and 3 have been sales.
Here’s a breakdown of recent trading of $TECH stock by insiders over the last 6 months:
- ROELAND NUSSE sold 17,040 shares for an estimated $960,388
- ROBERT V BAUMGARTNER sold 17,040 shares for an estimated $957,818
- AMY E. HERR sold 1,280 shares for an estimated $63,704
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
Bio-Techne Corporation Congressional Stock Trading
Members of Congress have traded $TECH stock 3 times in the past 6 months. Of those trades, 1 have been purchases and 2 have been sales.
Here’s a breakdown of recent trading of $TECH stock by members of Congress over the last 6 months:
- REPRESENTATIVE APRIL MCCLAIN DELANEY has traded it 3 times. They made 1 purchase worth up to $15,000 on 10/22 and 2 sales worth up to $30,000 on 08/01, 05/26.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
Bio-Techne Corporation Hedge Fund Activity
We have seen 303 institutional investors add shares of Bio-Techne Corporation stock to their portfolio, and 293 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- PRICE T ROWE ASSOCIATES INC /MD/ removed 2,527,348 shares (-22.2%) from their portfolio in Q2 2025, for an estimated $130,032,054
- SELECT EQUITY GROUP, L.P. removed 2,446,508 shares (-45.6%) from their portfolio in Q2 2025, for an estimated $125,872,836
- CITADEL ADVISORS LLC added 2,011,189 shares (+437.5%) to their portfolio in Q2 2025, for an estimated $103,475,674
- MILLENNIUM MANAGEMENT LLC added 1,640,649 shares (+inf%) to their portfolio in Q2 2025, for an estimated $84,411,391
- BLACKROCK, INC. removed 1,575,135 shares (-11.5%) from their portfolio in Q2 2025, for an estimated $81,040,695
- T. ROWE PRICE INVESTMENT MANAGEMENT, INC. added 1,238,095 shares (+inf%) to their portfolio in Q2 2025, for an estimated $63,699,987
- RGM CAPITAL, LLC added 1,189,192 shares (+117.6%) to their portfolio in Q2 2025, for an estimated $61,183,928
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Bio-Techne Corporation Analyst Ratings
Wall Street analysts have issued reports on $TECH in the last several months. We have seen 6 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- TD Cowen issued a "Buy" rating on 10/14/2025
- Evercore ISI Group issued a "Outperform" rating on 10/07/2025
- Citigroup issued a "Buy" rating on 08/21/2025
- Scotiabank issued a "Sector Outperform" rating on 07/11/2025
- Benchmark issued a "Buy" rating on 06/05/2025
- Wells Fargo issued a "Overweight" rating on 05/30/2025
To track analyst ratings and price targets for Bio-Techne Corporation, check out Quiver Quantitative's $TECH forecast page.
Bio-Techne Corporation Price Targets
Multiple analysts have issued price targets for $TECH recently. We have seen 8 analysts offer price targets for $TECH in the last 6 months, with a median target of $71.0.
Here are some recent targets:
- Kyle Boucher from TD Cowen set a target price of $70.0 on 10/14/2025
- Daniel Markowitz from Evercore ISI Group set a target price of $72.0 on 10/07/2025
- Conor McNamara from RBC Capital set a target price of $73.0 on 09/03/2025
- Patrick Donnelly from Citigroup set a target price of $70.0 on 08/21/2025
- Sung Ji Nam from Scotiabank set a target price of $75.0 on 07/11/2025
- Robert Wasserman from Benchmark set a target price of $75.0 on 06/05/2025
- Brandon Couillard from Wells Fargo set a target price of $59.0 on 05/30/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
